Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis

Multiple Sclerosis and Related Disorders

Volumn 1, Issue 2, 2012, Pages 87-94

  Singer, B ^a   Wray, S ^b   Miller, T ^c   Cascione, M ^d   Gupta, A ^e   Pardo, G ^f   Watsky, E ^g   Hayward, B ^h   Mercer, B ^h   Dangond, F ^h  

^a MISSOURI BAPTIST MEDICAL CENTER   (United States)

^b Hope Neurology MS Center   (United States)

^c Advanced Neurology of Colorado LLC   (United States)

^d Tampa Neurology Associates   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^g PFIZER INC   (United States)

^h EMD SERONO INC   (United States)

Author keywords

Beta interferon; Disease modifying therapies; Injection devices; Multiple sclerosis; Relapsingremitting; Self injection

Indexed keywords

BETA1A INTERFERON;

ADULT; AGED; ANXIETY; ARTICLE; DEPRESSION; DRUG DELIVERY SYSTEM; DRUG WITHDRAWAL; ELECTRONIC AUTOINJECTOR; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE HEMATOMA; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OPEN STUDY; PATIENT COMPLIANCE; PATIENT SAFETY; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RELAPSE; RELIABILITY; SELF INJECTION; SIDE EFFECT; UNITED STATES; URINARY TRACT INFECTION;

EID: 84863407917     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2011.11.002     Document Type: Article

References (15)

1. A. Al-Sabbagh, R. Bennet, C. Kozma, M. Dickson, and D. Meletiche Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database Journal of Neurology 255 Suppl. 2 2008 S79
2. A. Bayas, G. Japp, U. Fulda, and B.A. Kallmann Injection devices in the basic therapy of multiple sclerosis. Survey among neurologists, MS nurses and patients Nervenheilkunde 29 2010 57 62
3. B. Brochet, G. Lemaire, and A. Beddiaf Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices Revue Neurologique (Paris) 162 2006 735 740 (Pubitemid 44046655)
4. N.D. Chiaravalloti, and J. DeLuca Cognitive impairment in multiple sclerosis Lancet Neurology 7 2008 1139 1151
5. D. Cox, and J. Stone Managing self-injection difficulties in patients with relapsingremitting multiple sclerosis Journal of Neuroscience Nursing 38 2006 167 171
6. J.A. Cramer, B.J. Cuffel, V. Divan, A. Al-Sabbagh, and M. Glassman Patient satisfaction with an injection device for multiple sclerosis treatment Acta Neurologica Scandinavica 113 2006 156 162
7. V. Devonshire, T. Arbizu, B. Borre, M. Lang, A. Lugaresi, and B. Singer Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study BMC Neurology 10 2010 28
8. V. Devonshire, Y. Lapierre, R. Macdonell, C. Ramo-Tello, F. Patti, and P. Fontoura The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis European Journal of Neurology 18 2011 69 77
9. A. Lugaresi Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opinion on Drug Delivery 6 2009 995 1002
10. D. Mikol, M. Lopez-Bresnahan, S. Taraskiewicz, P. Chang, J. Rangnow, and Rebiject Study Group A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis Multiple Sclerosis 11 2005 585 591 (Pubitemid 41387705)
11. D.C. Mohr, A.C. Boudewyn, W. Likosky, E. Levine, and D.E. Goodkin Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject Annals of Behavioral Medicine 23 2001 125 132 (Pubitemid 32488430)
12. ® prefilled syringe in multiple sclerosis subjects BMC Neurology 11 2011 126
13. C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, and L. Kappos Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria Annals of Neurology 58 2005 840 846 (Pubitemid 41746873)
14. H.L. Tremlett, and J. Oger Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS Neurology 61 2003 551 554 (Pubitemid 37025380)
15. K. Treadaway, G. Cutter, A. Salter, S. Lynch, J. Simsarian, and J. Corboy Factors that influence adherence with disease-modifying therapy in MS Journal of Neurology 256 2009 568 576